Eli Lilly and Company, Johnson & Johnson, AbbVie, Gilead Sciences, Merck & Co., Inc., Pfizer, and McKesson are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares in companies that develop, manufacture, or sell medicines and related treatments. For investors, their value can be influenced by factors such as clinical-trial results, regulatory approvals, patents, and competition. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
NYSE LLY traded down $27.80 during mid-day trading on Thursday, reaching $1,390.19. 2,463,742 shares of the stock were exchanged, compared to its average volume of 2,947,631. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,453.00. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The stock has a 50 day simple moving average of $1,207.75 and a 200-day simple moving average of $1,097.85. The stock has a market cap of $1.31 trillion, a P/E ratio of 45.25, a P/E/G ratio of 1.76 and a beta of 0.40.
Read Our Latest Research Report on LLY
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of JNJ stock traded down $0.69 on Thursday, hitting $275.63. The stock had a trading volume of 4,132,770 shares, compared to its average volume of 7,944,761. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The stock has a market cap of $663.54 billion, a price-to-earnings ratio of 41.85, a price-to-earnings-growth ratio of 2.63 and a beta of 0.22. Johnson & Johnson has a 12-month low of $185.12 and a 12-month high of $282.02. The business has a 50 day moving average of $265.67 and a 200 day moving average of $247.74.
Read Our Latest Research Report on JNJ
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE ABBV traded down $0.47 during trading hours on Thursday, hitting $294.36. The company had a trading volume of 3,037,575 shares, compared to its average volume of 6,330,681. The firm has a market capitalization of $520.08 billion, a price-to-earnings ratio of 50.83, a PEG ratio of 1.30 and a beta of 0.20. AbbVie has a 52 week low of $190.75 and a 52 week high of $302.93. The firm has a 50 day simple moving average of $270.80 and a 200 day simple moving average of $238.28.
Read Our Latest Research Report on ABBV
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
NASDAQ:GILD traded down $3.84 during trading hours on Thursday, reaching $170.64. The company's stock had a trading volume of 4,221,102 shares, compared to its average volume of 6,826,180. The firm has a 50-day simple moving average of $152.29 and a 200-day simple moving average of $140.52. Gilead Sciences has a 1 year low of $116.88 and a 1 year high of $176.58. The firm has a market capitalization of $211.65 billion, a price-to-earnings ratio of -54.00 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38.
Read Our Latest Research Report on GILD
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of Merck & Co., Inc. stock traded down $0.74 during midday trading on Thursday, reaching $149.62. 4,602,432 shares of the company's stock traded hands, compared to its average volume of 10,631,634. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 12 month low of $84.35 and a 12 month high of $156.92. The company has a market cap of $369.14 billion, a PE ratio of 154.36, a price-to-earnings-growth ratio of 6.57 and a beta of 0.13. The stock has a 50 day moving average of $146.57 and a 200-day moving average of $127.26.
Read Our Latest Research Report on MRK
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Shares of NYSE PFE traded down $0.40 during mid-day trading on Thursday, hitting $30.39. 22,101,088 shares of the stock traded hands, compared to its average volume of 39,746,906. The stock has a fifty day moving average price of $28.69 and a 200-day moving average price of $26.86. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a market cap of $173.24 billion, a price-to-earnings ratio of 43.50, a PEG ratio of 2.04 and a beta of 0.31. Pfizer has a 52 week low of $23.62 and a 52 week high of $31.44.
Read Our Latest Research Report on PFE
McKesson (MCK)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Shares of MCK traded up $22.39 during mid-day trading on Thursday, reaching $1,091.84. The company had a trading volume of 586,089 shares, compared to its average volume of 916,639. McKesson has a 52 week low of $723.68 and a 52 week high of $1,121.50. The company has a market capitalization of $127.30 billion, a price-to-earnings ratio of 29.13, a price-to-earnings-growth ratio of 1.99 and a beta of 0.27. The firm has a 50-day moving average price of $931.17 and a 200 day moving average price of $865.74.
Read Our Latest Research Report on MCK
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
